Legend Biotech Medical Affairs

Who made you feel like you were #MoreThanMyeloma? Tag them below to thank them. ❤️#MyelomaActionMonth Special thanks to @LegendBiotech and @LegendUSMA for helping us amplify myeloma voices.

Myeloma is the 2nd most common blood cancer worldwide, but we are more than myeloma. Share what makes you #MoreThanMyeloma below! We thank Legend Biotech for helping us spread the facts. @LegendBiotech @LegendUSMA

March is #MyelomaActionMonth—a time to raise awareness and support myeloma patients and the broader community. We’re proud to collaborate with the International Myeloma Foundation (@IMFmyeloma) to amplify education and understanding. Join us in sharing why we’re #MoreThanMyeloma.

Our VP & Head of Early-Stage Drug Dev, Dong Geng, will participate in a panel on in vivo cell therapy Feb. 11 @ 1:20 p.m. at #IO360Summit. 📍 Track 2: Cell Therapy Plenary 🎤 In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment io360summit.com

Thank you to those who joined us during #Tandem26 and engaged with our data. Your continued partnership advances the science of cellular therapy and supports progress in care for patients with multiple myeloma. Looking forward to continuing the momentum at #ASCO26. #mmsm #CART

Robert Bowden (Johnson & Johnson) presents at #TANDEM26 on improved manufacturing outcomes with out-of-specification BCMA-directed #CART therapy in earlier lines of therapy. For more, link here: bit.ly/3NxfNI9. #mmsm

At #TANDEM26, Dr. Doris Hansen of @MoffittNews presents characterization and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: bit.ly/4qH1I9G. #mmsm.

Dr. Surbhi Sidana (@SurbhiSidanaMD) presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in len-refractory multiple myeloma patients in the CARTITUDE-4 trial. Link: bit.ly/49AV3HZ. #mmsm.

Dr. Doris Hansen from @MoffittNews presents at #TANDEM26 on bridging therapy response and pre-lymphodepletion plasma cell burden as determinants of BCMA-directed safety and efficacy outcomes in relapsed/refractory multiple myeloma. Link: bit.ly/3LOuExk. #mmsm.

Dr. Binod Dhakal (@bhemato) presents at #TANDEM26 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. For more, link here: bit.ly/4pSeNMc. #mmsm #CART

See Dr. Luciano Costa (@End_myeloma) at #TANDEM26 present long-term progression-free survival outcomes with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma in the CARTITUDE-4 study. For more, link here: bit.ly/3LY4fx6. #mmsm

Excited for the #TANDEM26 Annual Meeting and the chance to advance patient-centered innovation together. We hope you will connect with our Medical Affairs team at Booth #301 for those attending live in Salt Lake City. For more on our science: bit.ly/4sZ9Wvy. #mmsm #CART

We will present data on our #CART #CellTherapy for #MultipleMyeloma at #Tandem26 Meetings of @ASTCT and @CIBMTR in Salt Lake City. Six posters will highlight efficacy, safety, and real-world outcomes, supporting earlier use in the treatment journey. investors.legendbiotech.com/news-releases/…

An updated CARTITUDE-4 analysis published in @TheLancetOncol reports outcomes evaluating earlier use of our #CART #CellTherapy for #MultipleMyeloma, adding to the growing clinical evidence informing treatment decisions and future research. 🔗 thelancet.com/journals/lanon…

US-based authors: Dr. Binod Dhakal (@bhemato) of MCW and Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford

NEW in Lancet Oncology: Latest findings from CARTITUDE-4 study report on survival outcomes in patients with relapsed/refractory multiple myeloma treated with a BCMA #CART therapy as early as first relapse compared with standard of care. #mmsm Read more: bit.ly/4qJUkKp

ICYMI: we recently celebrated the opening of our new 32,000 square foot state-of-the-art cell therapy research facility in downtown Philadelphia that will help support Legend’s pipeline of next-generation cell therapies. For more about Legend’s pipeline: bit.ly/3XJDsqu.

A heartfelt thank you to all who joined us at #ASH25, attended sessions, and visited our posters. Together, we’re pushing boundaries in #CART therapy and accelerating better outcomes for patients with #mmsm and #lymsm.

Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: bit.ly/48fwXRi. #mmsm.